Iterum Therapeutics (ITRM) Competitors $1.08 +0.03 (+2.86%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.07 -0.01 (-1.30%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. DBVT, NBTX, DMAC, CGC, FULC, DERM, ACRS, IPHA, MOLN, and PBYIShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include DBV Technologies (DBVT), Nanobiotix (NBTX), DiaMedica Therapeutics (DMAC), Canopy Growth (CGC), Fulcrum Therapeutics (FULC), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Innate Pharma (IPHA), Molecular Partners (MOLN), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. DBV Technologies Nanobiotix DiaMedica Therapeutics Canopy Growth Fulcrum Therapeutics Journey Medical Aclaris Therapeutics Innate Pharma Molecular Partners Puma Biotechnology DBV Technologies (NASDAQ:DBVT) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership. Is DBVT or ITRM more profitable? Iterum Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -815.73%. Iterum Therapeutics' return on equity of 0.00% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-815.73% -106.07% -76.17% Iterum Therapeutics N/A N/A -90.85% Do analysts rate DBVT or ITRM? DBV Technologies presently has a consensus price target of $22.50, suggesting a potential upside of 181.95%. Iterum Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 362.96%. Given Iterum Therapeutics' higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor DBVT or ITRM? In the previous week, DBV Technologies had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Iterum Therapeutics. DBV Technologies' average media sentiment score of 0.26 beat Iterum Therapeutics' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, DBVT or ITRM? DBV Technologies has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500. Does the MarketBeat Community prefer DBVT or ITRM? DBV Technologies received 264 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. However, 62.95% of users gave Iterum Therapeutics an outperform vote while only 54.22% of users gave DBV Technologies an outperform vote. CompanyUnderperformOutperformDBV TechnologiesOutperform Votes40554.22% Underperform Votes34245.78% Iterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Do insiders & institutionals believe in DBVT or ITRM? 71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 1.9% of DBV Technologies shares are held by insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, DBVT or ITRM? Iterum Therapeutics has lower revenue, but higher earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$15.73M10.44-$72.73M-$5.00-1.60Iterum TherapeuticsN/AN/A-$24.77M-$1.31-0.82 SummaryIterum Therapeutics beats DBV Technologies on 9 of the 16 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.35M$6.46B$5.31B$7.35BDividend YieldN/A3.22%5.45%4.31%P/E Ratio-0.826.9521.9417.82Price / SalesN/A231.00380.9497.68Price / CashN/A65.6738.2634.64Price / Book-9.005.936.453.98Net Income-$24.77M$143.22M$3.22B$247.81M7 Day Performance-2.70%4.28%5.85%3.19%1 Month Performance-25.52%-13.11%-9.55%-7.70%1 Year Performance-24.48%-8.51%11.83%1.49% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics1.3815 of 5 stars$1.08+2.9%$5.00+363.0%-24.5%$37.35MN/A-0.8210DBVTDBV Technologies2.6185 of 5 stars$7.44+14.5%$22.50+202.4%+17.1%$153.03M$15.73M-1.6580Earnings ReportAnalyst ForecastShort Interest ↑NBTXNanobiotix1.7973 of 5 stars$3.17-3.1%$8.00+152.4%-38.3%$149.41M$36.22M0.00100Gap DownDMACDiaMedica Therapeutics1.2278 of 5 stars$3.48-0.6%$8.00+129.9%+48.1%$149.14MN/A-6.2120Short Interest ↑News CoverageGap DownCGCCanopy Growth2.2583 of 5 stars$0.93+1.1%$2.00+114.9%-85.0%$147.59M$276.75M-0.243,150Options VolumeNews CoverageFULCFulcrum Therapeutics2.2507 of 5 stars$2.72+8.4%$8.63+217.1%-51.9%$146.82M$80M-8.77100Short Interest ↓News CoveragePositive NewsDERMJourney Medical2.294 of 5 stars$6.96-3.2%$9.88+41.9%+79.6%$145.39M$56.13M-7.4090Short Interest ↑High Trading VolumeACRSAclaris Therapeutics1.826 of 5 stars$1.33-5.0%$11.67+777.2%-8.1%$143.53M$18.72M-2.56100Positive NewsGap UpIPHAInnate Pharma2.1212 of 5 stars$1.71-6.6%$11.50+572.5%-19.3%$143.35M$12.63M0.00220MOLNMolecular Partners1.6031 of 5 stars$3.54-0.8%$12.00+239.0%+19.6%$142.93M$4.97M-1.65180PBYIPuma Biotechnology3.5316 of 5 stars$2.83-2.4%$7.00+147.3%-42.9%$140.40M$230.47M5.90200Analyst Upgrade Related Companies and Tools Related Companies DBV Technologies Alternatives Nanobiotix Alternatives DiaMedica Therapeutics Alternatives Canopy Growth Alternatives Fulcrum Therapeutics Alternatives Journey Medical Alternatives Aclaris Therapeutics Alternatives Innate Pharma Alternatives Molecular Partners Alternatives Puma Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ITRM Stock Free ITRM Stock Alerts